Skip to main content

Cellnovo expands its base of potential users

By 17/02/2019June 4th, 2021No Comments

Cellnovo’s insulin cartridges are now refillable

People with diabetes with higher insulin requirements, including some with type 2 diabetes, will now be able to use the Cellnovo System

Cellnovo Group (Paris:CLNV) (“Cellnovo” or the “Company” CLNV:EN Paris), a medical technology company marketing the first connected diabetes management platform composed of an insulin micro-pump communicating via Bluetooth® with a locked-down Android™ smartphone, today announces that its insulin cartridges are now refillable. This will enable people with insulin needs exceeding the current cartridge capacity to use the Cellnovo System, including some people with type 2 diabetes.

Until now, patients using the Cellnovo System with daily insulin dose requirements over 50 units were obliged to use more than one cartridge every 3 days. This was leading to higher utilization costs and potentially limiting the adoption of the system by patients with higher insulin needs. They will now be able to refill the cartridge within three days of use and benefit from the quality of life offered by a miniaturized system, without any additional costs.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: “Enabling patients to refill their insulin cartridges allows us to offer the Cellnovo System to 100% of people with type 1 diabetes, and to some of people with type 2 diabetes. All current Cellnovo System users will have immediate access to these cartridges. This will contribute to the continuing commercial growth of the Company.”